Verrica Pharmaceuticals Inc. is a US-based dermatology therapeutics company that focuses on treating skin diseases. Their product candidate - VP-102 - has completed Phase II clinical trial for molluscum contagiosum treatment, is in Phase II clinical trial for common warts, and is used to treat external genital warts. Additionally, they collaborate with other companies to develop and commercialize their product candidates globally.